Truly innovative molecules, powered by QEMI — our genAI and fast-physics platform
At Aqemia, we pioneer a physics-first approach to drug discovery, eliminating the need for experimental training data and thus enabling generative AI to design truly novel molecules. By leveraging our unique fast physics, we reconcile speed and precision in molecular design and make large-scale exploration of chemical space possible.
Beyond AI for drug discovery
AI is revolutionizing how we learn from large amounts of data, yet each new drug discovery program involves a new target and a chemical space that has never been explored before.
And here’s the elephant in the room: when trained on past drugs, AI struggles to create medicines for new, unresolved targets and diseases.
We strongly believe that putting physics at the center is the key to unlocking treatments for untreated diseases. Our physics predicts interactions between future drugs and targets atom by atom — not by relying on resemblance to past cases.
The consequence: we are not slightly improving existing molecules.
Rooted in physics, our generative AI explores vast chemical spaces, unafraid of the unknown, free from bias, and tailored to each target.
Unique scalable physics
Physics offers the most accurate understanding of molecular interactions, but traditional methods are too slow for rational drug design at scale, thus forcing a trade-off between precision and speed.
Aqemia has the proprietary technology to resolve this.
QEMI delivers predictions with physics-level accuracy up to 10,000× faster than conventional methods — not through brute-force computing power, but through elegant and novel mathematics from quantum mechanics developed over 12 years of academic research at Oxford, Cambridge, and ENS/CNRS in Paris.
By uniting speed and precision, we make physics truly scalable, unlocking genuine molecular invention at scale and opening the way to far deeper exploration of chemical space.
Scaling up drug discovery
By understanding molecular interactions at scale, QEMI enables the invention of molecules tailored to new targets while remaining selective against anti-targets, addressing selectivity challenges and enabling wide therapeutic windows.
Continuously learning from every program, QEMI evolves over time, accelerating the discovery of differentiated therapies across many potential therapeutic areas.
This is rational molecule generation, grounded in science, built for scale.